Literature DB >> 30589079

Neoadjuvant Treatments for Advanced Resectable Melanoma.

Jessica Y Liu1, Michael Lowe2.   

Abstract

Neoadjuvant therapy has demonstrated promise as a treatment modality in resectable advanced-stage melanoma. Treatment has evolved beyond chemotherapy, with the utilization of biochemotherapy, immunotherapy, and targeted therapy in the neoadjuvant setting. These therapies have shown better progression-free survival and melanoma-specific survival when compared with patients that proceed directly to surgery. Ongoing clinical trials will continue to propel research forward to improve the available options for patients with resectable advanced regional disease.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  melanoma; neoadjuvant treatment

Mesh:

Year:  2018        PMID: 30589079     DOI: 10.1002/jso.25352

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.

Authors:  Yana G Najjar; Dustin McCurry; Huang Lin; Yan Lin; Yan Zang; Diwakar Davar; Arivarasan Karunamurthy; Joseph J Drabick; Rogerio I Neves; Lisa H Butterfield; Marc S Ernstoff; Igor Puzanov; Joseph J Skitzki; Jennifer Bordeaux; IlaSri B Summit; Jehovana O Bender; Ju Young Kim; Beiru Chen; Ghanashyam Sarikonda; Anil Pahuja; Jennifer Tsau; Zeni Alfonso; Christian Laing; James F Pingpank; Matthew P Holtzman; Cindy Sander; Amy Rose; Hassane M Zarour; John M Kirkwood; Ahmad A Tarhini
Journal:  Clin Cancer Res       Date:  2021-03-22       Impact factor: 13.801

2.  Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma.

Authors:  Anna M Czarnecka; Krzysztof Ostaszewski; Aneta Borkowska; Anna Szumera-Ciećkiewicz; Katarzyna Kozak; Tomasz Świtaj; Paweł Rogala; Iwona Kalinowska; Hanna Koseła-Paterczyk; Konrad Zaborowski; Paweł Teterycz; Andrzej Tysarowski; Donata Makuła; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.